ENHANCED ENTEROVIRUS SURVEILLANCE IN NEW YORK STATE FOLLOWING A CONFIRMED POLIOMYELITIS CASE IN JULY 2022

SA Ogbamikael¹, J Plitnick¹, E Rist¹, M Popowich¹, DM Lamson¹, M Fuschino¹, M McClenaghan², H Meek², D Gowie², J Wohlfahrt², BJ Anderson², B Backenson², S Byun², New York State Regional Office Working Group³, E Rosenberg⁴, K St. George¹. ¹Wadsworth Center, New York State Department of Health, Albany, NY; ²Bureau of Communicable Disease Control, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ³Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State Department of Health, Albany, NY; ⁴Metropolitan Area Regional Office, New York State N Long Island, NY; ⁴Office of Science, New York State Department of Health, Albany, NY

Introduction

- In July 2022, the Wadsworth Center detected poliovirus type 2 in the stool of an unvaccinated hospitalized patient with paralysis, see figure 1.
- CDC confirmed vaccine-derived poliovirus, Sabin-like virus type 2 (VDPV2).
- No relevant travel history, implying community acquired VDPV2.
- Wastewater surveillance detected further community VDPV2 transmission within some New York State counties, see figure 2.
- To help investigate the extent of virus circulation, the New York State Department of Health initiated an enhanced enterovirus surveillance program.

Enterovirus VP1 Region Gel Electrophoresis




Figure 1. PCR-amplified VP1 region of poliovirus Sabir type 2 in patient sample identified using gel electrophoresis



Figure 2. Counties with detections of poliovirus type 2 genetically linked to the virus isolated from the case are indicated in red: Sullivan (A), Orange (B), Rockland (C), Kings and Queens (D), and Nassau (E).

https://www.health.ny.gov/diseases/communicable/polio/docs/waste_water_surveillan

Methods

Testing Strategy


- The preferred sample type was stool, but cerebrospinal fluid (CSF) and respiratory swabs were also received and tested.
- Samples were extracted on the bioMerieux easyMAG® or EMAG®.
- cDNA synthesis was performed using the Quanta qScript[™] cDNA Synthesis Kit.
- Real-time RT-PCR for initial enterovirus (EV) detection was performed on Applied Biosystems[™] 7500 Dx Real-time PCR System.
- All real-time EV positive samples were reflexed to molecular serotyping by semi-nested conventional PCR, followed by sequencing of a portion of the VP1 gene (modified from Nix *et al.*) from either the 1st or 2nd round of amplification.
- NCBI BLAST analysis of the sequence was used to determine molecular serotype.


Surveillance Strategy

- Patients Under Investigation (PUIs) included:
 - Any patient with mild polio-like symptoms, unimmunized or incompletely immunized, who lived or worked in areas of wastewater positivity or low vaccination rates AND tested positive for EV.
 - Any patient with symptoms consistent with acute flaccid myelitis (AFM).
 - EV-positive meningitis cases from counties with polio positive wastewater or low vaccine rates.
- Diaper Study Patient samples included:
 - Stool collected from healthy diapered patients at pediatrician well visits.
 - Participants from targeted counties with wastewater positivity.

Routine Enterovirus Surveillance included:

- Special cases and autopsy samples that tested positive for EV.
- Enterovirus/rhinovirus positive samples detected on sample-to-answer multiplexed panels that do not distinguish those two viruses.
- EV testing on hospitalized patients with encephalitis.








Figure 4. Enterovirus serotypes detected by sample type. EV-D68 was the only serotype exclusively detected in respiratory samples during the surveillance period.




Figure 5. Enterovirus serotypes identified from symptomatic

enterovirus surveillance (PUIs). Non-polio enteroviruses accounted for all enterovirus positive cases during the surveillance period.

Table 1. Enterovirus serotypes identified from asymptomatic Diaper Study samples.

	NYS Counties		
Enterovirus Serotype	Orange	Rockland	Total
Coxsackievirus A5	2		2
Echovirus 14	1	1	2
Echovirus 6	2		2
Echovirus 9	1		1
Enterovirus A71	1		1
Not Detected	15	9	24
Inconclusive	4		4
TOTAL	26	10	36

• Among EV-positive samples: 20 were species A, 80 species B, 4 species C (non-polio), and 27 species D; but 0 additional polioviruses were identified.

Even though VDPV2 was detected in a symptomatic patient and wastewater surveillance showed community transmission in 2022, no additional cases of poliovirus were identified during subsequent human testing.

- which was exclusively found in respiratory samples.
- pattern of 2-year epidemic waves.

- surveillance testing in New York State.

Nix, W Allan *et al.* "Sensitive, semi-nested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens." Journal of clinical microbiology vol. 44,8 (2006): 2698-704. doi:10.1128/JCM.00542-06. http://dx.doi.org/10.1128/JCM.00542-06 Link-Gelles, Ruth *et al.* "Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022." MMWR. Morbidity and mortality weekly report vol. 71,33 1065-1068. 19 Aug. 2022, doi:10.15585/mmwr.mm7133e2 http://dx.doi.org/10.15585/mmwr.mm7133e2 Poliovirus Wastewater Surveillance Report (April 15, 2024). https://www.health.ny.gov/diseases/communicable/polio/docs/waste water surveillance report. pdf Kimura, M. "A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences." Journal of molecular evolution vol. 16,2 (1980): 111-20. doi:10.1007/BF01731581. https://doi.org/10.1007/BF01731581 Kumar, Sudhir et al. "MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms." Molecular biology and evolution vol. 35,6 (2018): 1547-1549. doi:10.1093/molbev/msy096. <u>https://doi.org/10.1093/molbev/msy096</u>

The authors would like to thank the Wadsworth Center AGTC Sequencing Core for performing sequencing assays, and Dr. Patrick Bryant and Lynsey Schoultz for performing poliovirus PCR assays on wastewater extracts.

Figure 6. Poliovirus vaccination status across PUIs tested during the surveillance period.

Department

Wadsworth Center

Results Continued



Figure 7. Partial VP1 sequence analysis of CoxB4 samples compared to EV-A (CoxA16), EV-B (CoxB4 & CoxA9), EV-C (CoxA21), and EV-D (EVD68). Evolutionary history was inferred by using the Maximum Likelihood method and Kimura 2-parameter model (Kimura et al.). Percentage of trees in which the associated taxa clustered together is shown next to the branches; values <70 not displayed. There were a total of 220 positions in the final dataset. Evolutionary analyses were conducted in MEGA X (Kumar et al.).

Reduced sensitivity of the VP1 sequencing assay identified variations at the 3' end of the amplicons in some of the CoxB4 samples (Red).

Overall Results

- An additional 279 samples were tested under routine surveillance procedures and 63

• 15 Coxsackie B4 viruses in 2023 had sequence variations at the 3' end of the VP1 amplicon causing a mismatch and decreased sensitivity for the sequencing primer.

Conclusion

• Surveillance data demonstrated enteroviruses to have multiple tropisms except EV-D68,

• In 2022, EV-D68 circulated statewide but was not detected in 2023, following a known

 In 2023, Coxsackievirus B4 was widely circulating. Sequencing from the larger 1st round PCR product was at times necessary to overcome reduced sensitivity due to changes at the 3' end of the VP1 second round amplicon, identified by sequence analysis.

• Challenge to obtaining Diaper Study samples were low number of participants. However, the 25% EV-positivity rate in these asymptomatic patients was surprising.

• The enhanced EV surveillance improved communication between the Wadsworth Center Virology Laboratory and epidemiology colleagues, resulting in improved AFM

• Wastewater surveillance for poliovirus is ongoing in New York. Poliovirus was last detected in a New York State sewershed sample in February of 2023.

References

Acknowledgments